Status:
COMPLETED
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
The Salah Foundation
Sean M. Healey & AMG Center for ALS
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a single center, open label, 12-week study of inosine treatment. Inosine treatment leads to an increase in the levels of urate (uric acid) in the blood. The primary objective of the study is ...
Detailed Description
Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative disease for which there is no cure. Multiple lines of evidence have implicated oxidative stress in the pathophysiology of ALS. Urate (...
Eligibility Criteria
Inclusion
- Age 18 years or older.
- Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1).
- Capable of providing informed consent and following trial procedures.
- Serum urate \< 5.5 mg/dl at screening (i.e. below the population median serum urate levels).
- Willingness to undergo magnetic resonance spectroscopy (MRS) at Baseline and at Week 12 of the study.
- Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and 3 months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.
Exclusion
- History of urolithiasis.
- Urine pH \< 5.5 at screening (as acidic urine is a major determinant of uric acid urolithiasis).
- Urate crystalluria at Screening.
- History of gout.
- History of stroke or myocardial infarction.
- History of symptomatic coronary artery disease (e.g. angina pectoris) or symptomatic peripheral arterial disease within 1 year prior to Screening.
- Symptomatic congestive heart failure with a documented ejection fraction below 45%.
- Poorly controlled arterial hypertension (SBP\>160mmHg or DBP\>100mmHg at Screening).
- Contraindications to undergo magnetic resonance spectroscopy (MRS) at Baseline and at Week 12 of the study such as history of claustrophobia, inability to lie flat for approximately one hour, or metal implants (metal pins or plates, extensive non-removable dental work, cerebral aneurysm clips, pacemaker).
- Women who are pregnant or lactating.
- The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to PI judgment, or a history of active substance abuse within the prior year.
- Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.
- Use of the following within 30 days prior to Screening: inosine, allopurinol, probenecid, more than 300mg vitamin C daily (note that a subject may take a standard multivitamin up to one tablet or capsule daily). Use of thiazides is permissible as long as the subject is on a stable dose from 1 week prior to Screening.
- Known hypersensitivity or intolerability to inosine.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT02288091
Start Date
January 1 2015
End Date
March 1 2016
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114